Dyne therapeutics competitors
WebSep 6, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
Dyne therapeutics competitors
Did you know?
WebApr 4, 2024 · Dyne Therapeutics currently has a consensus target price of $25.83, suggesting a potential upside of 133.79%. Given Dyne Therapeutics’ higher possible upside, equities analysts plainly believe ... WebApr 3, 2024 · “ Dyne’s breakthrough approach brings the power of modern oligo therapeutics and other payloads to patients with serious muscle diseases," said Jason Rhodes, a partner at Atlas Venture and ...
WebDyne Therapeutics’s Profile, Revenue and Employees. Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Dyne Therapeutics’s primary competitors include Avidity Biosciences, Sarepta Therapeutics, Neurana and 6 more. WebFind company research, competitor information, contact details & financial data for Dyne Therapeutics, Inc. of Waltham, MA. Get the latest business insights from Dun & …
WebNov 3, 2024 · A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In June 2024, Dyne … WebDyne Therapeutics has 5 employees at their 1 location and $165 m in total funding,. See insights on Dyne Therapeutics including office locations, competitors, revenue, …
WebDyne Therapeutics Inc Working Capital Per Revenue on the trailing twelve month basis from the forth quarter 2024 to forth quarter 2024, Trends and Ranking, Fundamental Ratios - CSIMarket ... Dyne Therapeutics Inc 's Competition Performance; Dyne Therapeutics Inc 's Competitors Results; DYN's Competitors Stock Performance;
WebApr 4, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they … starhub incoming overseas call chargesWebDyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for … starhub incoming international call ratesWebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … starhub idd call to malaysiaWebMar 23, 2024 · Dyne Therapeutics sets IPO terms, to offer 10.3 million shares priced at $16 to $18 each. Sep. 10, 2024 at 7:12 a.m. ET by Ciara Linnane. peter bright ocala flWebFeb 9, 2024 · Competitors: Unknown. Dyne Therapeutics Reviews ... Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne Therapeutics company profile. All content is posted anonymously by employees working at Dyne Therapeutics. peter brightwellWebMay 16, 2024 · About Dyne Therapeutics. Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... Sector and Competitors. 1st jan. Capi. (M$) DYNE THERAPEUTICS, INC.-26.40%: 497: MODERNA, INC.-13.39%: 59 996: … starhub iphone 13 cisWebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … peter brightbill wells fargo